The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients

Phase IV Study on Predictive Markers for the Effectiveness of Nateglinide or Acarbose for Controlling Post-Prandial Glucose in Type 2 Diabetics Already on Optimized Insulin Glargine Therapy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00437918

Enrollment

Registered

2007-02-21

Start date

2007-01-31

Completion date

2008-03-31

Last updated

2008-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus

Brief summary

In type 2 diabetic patients, tight blood glucose control often requires both fasting and post-prandial glucose control separately. In the diabetic patients already on the insulin glargine treatment for the control of fasting blood glucose, additional measures for the control of post-prandial glucose level are often required. Nateglinide and acarbose are frequently used for this purpose. We hypothesized that the short acting sulfonylurea nateglinide may be more efficacious in diabetic patients with appreciable endogenous insulin secretion, while acarbose may be more efficacious in patients with lower endogenous insulin secretion. And we also want to clarify the clinical and biochemical parameters that can predict the responsiveness to each agent in this multi-center randomized open cross-over clinical study.

Interventions

DRUGnateglinide

DRUGacarbose

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Korean * Type 2 diabetes mellitus * No prior history of diabetic ketoacidosis * HbA1c between 7.5-10.0%

Exclusion criteria

* Type 1 diabetes mellitus * Gestational diabetes mellitus * Secondary diabetes mellitus * Severe hyperglycemia with symptoms * Severe chronic diabetic complications (PDR,s-Cr\>1.3mg/dL)

Design outcomes

Primary

Measure	Time frame
7 point SMBG (self monitoring of blood glucose)	—

Secondary

Measure	Time frame
HOMA-beta for predicting the effectiveness of each agents	—

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026